Clinical trialNCT06708949RecruitingPhase 2Interventional

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

SponsorM.D. Anderson Cancer CenterEnrollment15Renal Cell Carcinoma, Clear Cell

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eric Jonasch, MD
M.D. Anderson Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
David McDermott, MD
Recruiting
Duke University Medical Center
Durham, North Carolina, United States
Michael Harrison, MD
Recruiting
Penn Medicine Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Lin Mei, MD
Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Brian Rini, MD
Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Hans Hammers, MD
Recruiting
the University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Eric Jonasch, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BMS-986213Drugs NivolumabIpilimumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Mar 2025
Primary completion: 15 Dec 2026
Completion: 15 Dec 2028
Last update posted: 14 May 2026
Registered enrollment: 15
Registry id: NCT06708949

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.